Amoxiclav and itraconazole tablet overdose and acute kidney injury
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
amoxicillin clavulanate itraconazole overdose acute kidney injury
Searching the Web
amoxiclav itraconazole overdose acute kidney injury nephrotoxicity mechanism management
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
amoxicillin clavulanate acute kidney injury interstitial nephritis
Reading File
Reading File
I now have comprehensive data to write a thorough answer. Let me compile everything.
Amoxiclav & Itraconazole Overdose and Acute Kidney Injury
Overview
Amoxiclav (amoxicillin-clavulanate) and itraconazole have distinct nephrotoxic profiles when taken in excess. Understanding them separately — and their potential interaction — is important for clinical management.
1. Amoxiclav (Amoxicillin-Clavulanate) Overdose → AKI
Mechanisms of Renal Injury
Excessive doses of amoxicillin-clavulanate can injure the kidney through two primary mechanisms:
a) Crystalluria → Obstructive Nephropathy
Amoxicillin can precipitate in renal tubules, forming crystals (classically described as "straw floor broom" shaped on microscopy). This causes tubular obstruction and downstream injury, potentially progressing to acute renal failure.
- Comprehensive Clinical Nephrology 7e lists amoxicillin directly in the drug-induced crystalluria table
- National Kidney Foundation Primer on Kidney Diseases 8e confirms amoxicillin crystal morphology and its role in obstructive nephropathy
Risk is amplified by: dehydration, concentrated urine (low urine flow), high IV doses, and pre-existing kidney disease.
b) Acute Interstitial Nephritis (AIN)
Penicillins (including amoxicillin) are among the most common antibiotic causes of immune-mediated AIN. The mechanism is a delayed-type (Type IV) hypersensitivity reaction targeting renal tubulo-interstitial tissue.
Clinical features of penicillin-associated AIN include:
- Classic triad (present in <33% of cases): fever, maculopapular rash, eosinophilia
- Rise in serum creatinine over days to weeks
- Urinalysis: mild-moderate proteinuria, hematuria, WBC casts, eosinophiluria
- Occasionally: flank pain (from capsule distension), oliguria in severe cases
- DRESS syndrome association (drug rash, eosinophilia, systemic symptoms) — interstitial nephritis occurs in up to 40% of persistent DRESS cases
Goldman-Cecil Medicine notes that kidney injury in AIN is often asymptomatic initially, with substantial dysfunction already present by the time of diagnosis. Course progresses over days-weeks, and can be precipitous in re-exposure.
c) High-Dose IV Amoxicillin → Direct Tubular Toxicity
High-dose IV amoxicillin (HDIVA) can cause oliguric renal failure via tubular injury distinct from AIN — StatPearls / NCBI confirms this mechanism.
Overdose Management (Amoxiclav)
| Step | Action |
|---|---|
| Stop the drug | Immediate discontinuation is critical |
| Hydration & diuresis | Vigorous IV fluids to reduce tubular drug concentration and prevent crystalluria |
| Urinary alkalinization | May reduce amoxicillin crystallization |
| Supportive care | Monitor renal function (creatinine, urine output) |
| Hemodialysis | Consider in severe overdose or significant renal impairment — amoxicillin is dialyzable |
| Corticosteroids | Considered for confirmed AIN (prednisolone ~1 mg/kg/day) if no improvement after drug withdrawal |
2. Itraconazole Overdose → AKI
Renal Profile
Itraconazole is not directly nephrotoxic — this is a key clinical distinction from amphotericin B and aminoglycosides. Key facts:
- Itraconazole is extensively hepatically metabolized — no dose reduction needed in renal failure
- Plasma concentrations do not increase in renal insufficiency or decrease with hemodialysis
- Urine concentrations of bioactive drug are negligible (very little active drug appears in urine)
- Fitzpatrick's Dermatology 5e explicitly states: "Renal insufficiency and renal dialysis have no influence on the drug plasma concentration"
- Lippincott Illustrated Reviews Pharmacology confirms: "Itraconazole and posaconazole are metabolized by the liver and are not associated with nephrotoxicity"
- The IV formulation (which uses the vehicle sulfobutyl ether β-cyclodextrin) should be avoided when CrCl < 30 mL/min due to potential accumulation of the vehicle — though the oral tablet/capsule formulation does not carry this restriction
Indirect Renal Risk: CYP3A4 Inhibition
This is where itraconazole becomes clinically important in the context of AKI:
Itraconazole is a potent CYP3A4 and P-glycoprotein inhibitor. In overdose or even therapeutic use, it can dramatically increase plasma levels of co-administered nephrotoxic drugs including:
- Cyclosporine, tacrolimus, sirolimus (calcineurin inhibitors) → nephrotoxicity
- Statins (except pravastatin) → rhabdomyolysis → AKI
- A 2–10× dose reduction of affected co-medications may be required
3. Combined Overdose Considerations
When both drugs are taken in overdose together:
| Concern | Detail |
|---|---|
| Additive AKI risk | Amoxiclav's direct renal injury (crystalluria, AIN) combines with itraconazole's indirect CYP3A4-mediated drug interactions |
| Itraconazole raises amoxicillin levels? | Unlikely — amoxicillin is not primarily CYP3A4 metabolized (it is renally excreted unchanged); this interaction is minimal |
| Hepatotoxicity | Both drugs independently carry hepatotoxic risk; combined overdose warrants LFT monitoring |
| Volume of distribution | Neither is fully dialyzable in standard settings; supportive care is primary |
4. AKI Recognition & Monitoring
Apply KDIGO AKI staging criteria:
| Stage | Creatinine | Urine Output |
|---|---|---|
| 1 | ≥1.5× baseline or ≥0.3 mg/dL rise in 48h | <0.5 mL/kg/h for 6–12h |
| 2 | ≥2× baseline | <0.5 mL/kg/h for ≥12h |
| 3 | ≥3× baseline or ≥4.0 mg/dL | <0.3 mL/kg/h for ≥24h or anuria ≥12h |
Key investigations:
- Serum creatinine, BUN, electrolytes (K⁺ — risk of hyperkalaemia)
- Urinalysis + microscopy (crystals, casts, eosinophils)
- Urine output monitoring
- CBC (eosinophilia in AIN), LFTs (both drugs)
- Renal ultrasound (to assess for obstruction in crystalluria)
- Consider renal biopsy if diagnosis uncertain or no recovery after drug withdrawal
5. Summary
| Feature | Amoxiclav | Itraconazole |
|---|---|---|
| Direct nephrotoxicity | Yes (crystalluria, AIN, tubular injury at high dose) | No |
| Indirect renal risk | — | CYP3A4 inhibition → elevated levels of nephrotoxic co-drugs; rhabdomyolysis via statins |
| IV formulation renal risk | Dose adjustment in CKD | Avoid if CrCl <30 mL/min (vehicle accumulation) |
| Dialyzability | Partially dialyzable | Not significantly removed by dialysis |
| Dose reduction in CKD | Yes (dose-adjust by GFR) | No (oral form) |
| Key overdose treatment | Hydration, diuresis, stop drug; HD if severe | Supportive; address CYP3A4-mediated drug interactions |
Sources: Comprehensive Clinical Nephrology 7e; Goldman-Cecil Medicine; Katzung's Basic & Clinical Pharmacology 16e; National Kidney Foundation Primer on Kidney Diseases 8e; Fitzpatrick's Dermatology 5e; Lippincott Illustrated Reviews Pharmacology; StatPearls (NCBI).
This is a shared conversation. Sign in to Orris to start your own chat.